EA201991205A1 - COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN THE 20 EXON OF EGFR OR HER2 - Google Patents

COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN THE 20 EXON OF EGFR OR HER2

Info

Publication number
EA201991205A1
EA201991205A1 EA201991205A EA201991205A EA201991205A1 EA 201991205 A1 EA201991205 A1 EA 201991205A1 EA 201991205 A EA201991205 A EA 201991205A EA 201991205 A EA201991205 A EA 201991205A EA 201991205 A1 EA201991205 A1 EA 201991205A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
egfr
exon
compounds
cancer cells
Prior art date
Application number
EA201991205A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062326 external-priority patent/WO2018094225A1/en
Publication of EA201991205A1 publication Critical patent/EA201991205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее раскрытие предлагает способы лечения рака у пациента, у которого определено наличие мутации в 20 экзоне EGFR и/или HER2, такой как инсерционная мутация, путем введения ингибитора тирозинкиназы третьего поколения, такого как позиотиниб или афатиниб.The present disclosure provides methods for treating cancer in a patient who has a mutation in exon 20 of EGFR and / or HER2, such as an insertion mutation, by introducing a third generation tyrosine kinase inhibitor such as positionotinib or afatinib.

EA201991205A 2017-10-16 2017-11-17 COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN THE 20 EXON OF EGFR OR HER2 EA201991205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572716P 2017-10-16 2017-10-16
PCT/US2017/062326 WO2018094225A1 (en) 2016-11-17 2017-11-17 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Publications (1)

Publication Number Publication Date
EA201991205A1 true EA201991205A1 (en) 2019-11-29

Family

ID=68653639

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991205A EA201991205A1 (en) 2017-10-16 2017-11-17 COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN THE 20 EXON OF EGFR OR HER2

Country Status (1)

Country Link
EA (1) EA201991205A1 (en)

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
CY1122456T1 (en) MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
MX2021011948A (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions.
EA201792529A1 (en) Thyrosine Kinase Inhibitors
EA201890730A1 (en) DERIVATIVES OF PYRAZOLOPYRIMIDINE AS BTK INHIBITORS FOR THE TREATMENT OF MALIGNANT NORODUCTURE
MX2016012097A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
EA201390550A1 (en) METHODS OF INHIBITING PROLIFERATION OF CELLS IN EGFR-STIMULATED MALIGNANT TUMORS
EA201791946A1 (en) TREATMENT OF THE CHRONIC REACTION "TRANSPLANTATE AGAINST THE OWNER" WITH THE USE OF SYK INHIBITORS
UA107667C2 (en) Medical compounds stimulating activity of pyruvate kinase m2, compositions on their basis and use in the treatment of cancer
MX2019013634A (en) Compositions and methods for treating cancer with atypical braf mutations.
MX2017012824A (en) Treatment of lung cancer with inhibitors of glutaminase.
ZA201907225B (en) Treatment of her2 positive cancers
MX2019010149A (en) Inhibition of smarca2 for treatment of cancer.
MX2023000191A (en) Methods of making and using pde9 inhibitors.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EA201591395A1 (en) RANGE OF EVAPORATORS FOR WATER TREATMENT SYSTEM
MX2020003126A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
BR112022017508A2 (en) EGFR, KRAS, BRAF AND OTHER TARGET INHIBITORS AND THEIR USE
PH12021551276A1 (en) Combination therapy for the treatment of cancer
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2021012705A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations.